Real-World Use of Teprotumumab and Tocilizumab in Moderate-to-Severe Steroid-Resistant Thyroid Eye Disease

Abstract

Clinical Thyroidology®Vol. 35, No. 9 Thyroid Eye DiseaseReal-World Use of Teprotumumab and Tocilizumab in Moderate-to-Severe Steroid-Resistant Thyroid Eye DiseaseAnupam KotwalAnupam KotwalDivision of Diabetes, Endocrinology, and Metabolism, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.Search for more papers by this authorPublished Online:13 Sep 2023https://doi.org/10.1089/ct.2023;35.364-367AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 35Issue 9Sep 2023 Information© Copyright 2023, Mary Ann Liebert, Inc.To cite this article:Anupam Kotwal.Real-World Use of Teprotumumab and Tocilizumab in Moderate-to-Severe Steroid-Resistant Thyroid Eye Disease.Clinical Thyroidology®.Sep 2023.364-367.http://doi.org/10.1089/ct.2023;35.364-367Published in Volume: 35 Issue 9: September 13, 2023PDF download